Intest Res.  2022 Jan;20(1):150-155. 10.5217/ir.2020.00148.

Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Affiliations
  • 1Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
  • 2Department of Respiratory Medicine, Tokyo Women’s Medical University, Tokyo, Japan
  • 3Division of Nephrology, Department of Medicine, Tokyo Women’s Medical University, Tokyo, Japan
  • 4Department of Blood Purification, Tokyo Women’s Medical University, Tokyo, Japan
  • 5Primary Care Center, Tokyo Women’s Medical University, Tokyo, Japan

Abstract

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

Keyword

COVID-19; Granulocyte and monocyte adsorptive apheresis; Ulcerative colitis
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr